Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
West China Hospital
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
63High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07111221CT.gov Portal Inflow Modulation Prior to Liver Transplantation in Patients With Increased Risk of Intraoperative Blood Loss | — | Recruiting | — | — | — |
NCT04208776CT.gov Efficacy of Combination of Midodrine With Propranolol in Preventing First Bleed in Decompensated Cirrhotics With Severe Ascites. | — | Completed | — | — | — |
NCT04140591CT.gov Proton Pump Inhibitor Plus Propranolol Versus Proton Pump Inhibitor Alone on Peptic Ulcer Healing in Patients With Liver Cirrhosis | — | Terminated | — | — | — |
NCT02923336CT.gov Evaluation of Gastrointestinal Transit Pre and Pos Treatment With Non Selective Betablocker in a Population of Cirrhotics | — | Unknown | — | — | — |
NCT01897051CT.gov Rifaximin and Propranolol Combination Therapy Versus Propranolol Monotherapy in Cirrhotic Patients | — | Unknown | — | — | — |
NCT06977685CT.gov Effect of Non-Selective Beta-Blockers on Outcomes in Cirrhosis Patients After Hospitalization: A Retrospective Cohort Using Target Trial Design | — | Active Not Recruiting | — | — | — |
NCT00332904CT.gov Effect of Betablocker or Aldosterone Antagonist Therapy on Patients With Liver Cirrhosis | — | Unknown | — | — | — |
NCT01134692CT.gov Probiotics for Portal Hypertension | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cirrhosis Of Liver
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Apsolol (this asset) | West China Hospital | Approved | BB · 67 |
| Veruprevir | AbbVie | P3 | A |
| Gly-Gly-Gly-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-Nh2 (4-9 Disulfide) | General Hospital of Shenyang Military Region | P4 | BBB |
| Tolvaptan | Institute of Liver and Biliary Sciences, India | P4 | BBB |
| Ribavirin | Peking University People's Hospital | P4 | BBB |
| Cholyl-Lysl-Fluorescein | Norgine | P3 | BBB |
| Normal Human Serum Albumin | King George's Medical University | P4 | BBB |
| Ombitasvir | AbbVie | P3 | BBB |
| Dasabuvir | AbbVie | P3 | BBB |
+42 more in the Cirrhosis Of Liver cohort
Other indications for Apsolol
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Esophageal Varices | — | P4 | BBB · 74 |
| Migraine Disorder | — | P4 | BBB · 74 |
| Esophageal Varices With Bleeding | — | P4 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Apsolol in Cirrhosis Of Liver. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/apsolol-cirrhosis-of-liver
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →